Welcome to our dedicated page for Usana Health Sciences SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. (NYSE: USNA) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its nutrition-focused business, financial condition, and governance. This page centralizes those SEC filings and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
USANA’s current reports on Form 8-K include disclosures about preliminary financial results, updated net sales guidance, and leadership transitions, such as changes in the Chief Executive Officer role. Other 8-K filings describe credit agreements, financial covenants, and the posting of Management Commentary documents and conference call details related to quarterly results. These filings complement the company’s earnings releases and provide context on how management views performance in its direct selling and direct-to-consumer segments.
Investors can also use this page to access USANA’s periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, where available. These documents typically contain segment information, risk factor discussions, and explanations of non-GAAP measures such as Adjusted EBITDA and Adjusted diluted earnings per share, which USANA references in its communications.
Stock Titan’s platform enhances these filings with AI-generated highlights that explain key sections, summarize complex tables, and surface notable items such as changes in outlook, capital structure, or significant agreements. Users can quickly locate information on topics like net sales trends, credit facilities, or integration costs related to acquisitions such as Hiya, and can review insider-related disclosures when Forms 3, 4, or 5 are filed. Real-time updates from EDGAR help ensure that new USANA filings appear promptly with concise explanations.
USANA Health Sciences reports a diversified health and wellness business built around nutritional supplements, functional foods and personal care products sold globally. In 2025, the company generated $925 million in net sales and ended the year with about 387,000 active core nutritional Customers.
Mainland China is the largest market, contributing roughly 41.3% of net sales, with about 75.7% of consolidated net sales generated outside the United States. The business is now organized into two reportable segments: core nutritional and Hiya direct-to-consumer, complemented by smaller brands Rise and Oola.
USANA acquired a 78.85% interest in Hiya in December 2024, adding a subscription-based children’s wellness brand and accelerating its shift to an omni‑channel model that includes direct selling, direct‑to‑consumer, third‑party marketplaces and retail. As of January 3, 2026, Hiya had approximately 181,700 active Monthly Subscribers.
The company highlights ongoing R&D investment of $10.7 million in 2025, in‑house manufacturing for about 56% of products, and a revamped Brand Partner Compensation Plan launched in 2025 to enhance earning opportunities and customer growth. Management emphasizes growth initiatives in China, India, and new international markets, while expanding Hiya and Rise into online marketplaces and retail.
USANA also outlines extensive regulatory, legal, and compliance risks tied to dietary supplement rules, direct selling scrutiny by the FTC, and evolving direct selling and health‑product regulation in China, where operations run through its BabyCare subsidiary.
USANA Health Sciences' chief information officer, Peter Benedict, sold 4,553 shares of company common stock in an open-market transaction. The shares were sold at a weighted average price of $19.3848 per share, with individual trade prices ranging from $19.29 to $19.415. Following this sale, Benedict reported owning no shares of USANA common stock directly.
USNA filed a Form 144 reporting proposed sales of its common stock by insiders and related parties. The filing lists proposed sales of restricted common stock dated
The filing also records a sale by Peter G. Benedict of 2,673 common shares on
USANA Health Sciences' Chief Operating Officer Walter Noot reported equity award activity involving restricted stock units and common stock. On February 27, 2026, he exercised or converted 7,422 restricted stock units, each representing a right to receive one share of USANA common stock.
This conversion resulted in the acquisition of 7,422 shares of common stock at no exercise price, and a remaining balance of 75,130 restricted stock units held directly after the transaction. Following the stock acquisition, 3,144 common shares were disposed of at $21.52 per share to satisfy tax obligations by delivering shares.
After these transactions, Noot directly owned 9,256 shares of USANA common stock. Footnotes state that the restricted stock units vest 25% on the anniversary of February 27, 2025, linking these movements to the vesting schedule of prior equity awards.
USANA Health Sciences chief commercial officer Brent Neidig reported equity award activity involving restricted stock units and common shares. He exercised 6,747 restricted stock units, each representing a right to receive one USANA common share, and acquired 6,747 common shares at no cash price. On the same date, 2,993 common shares were withheld at $21.52 per share to satisfy tax obligations related to the award, leaving him with 7,513 directly owned common shares and 67,447 restricted stock units. The restricted stock units vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences Chief People Officer Paul A. Jones reported equity compensation activity involving restricted stock units and common shares. On February 27, 4,596 restricted stock units were exercised and converted into 4,596 shares of common stock at a price of $0.00 per share. A separate transaction on the same date disposed of 1,349 common shares at $21.52 per share to cover tax obligations through share withholding. After these transactions, Jones directly held 46,611 restricted stock units and 12,374 shares of common stock. Each restricted stock unit represents a contingent right to receive one share of USANA common stock.
USANA Health Sciences' chief financial officer IIEKKING G DOUG reported equity award activity. On February 27, 2026, he exercised 7,469 Restricted Stock Units, converting them into the same number of common shares at $0.00 per share. Following this conversion, his directly held common stock position was 10,391 shares before a separate tax transaction. On the same date, 5,031 common shares were disposed of at $21.52 per share to cover tax obligations, leaving him with 5,360 common shares held directly. Footnotes state each restricted stock unit represents one share of common stock and that these units vest 25% on the anniversary of February 27, 2025.
USANA Health Sciences chief legal officer Joshua Foukas reported equity compensation activity tied to restricted stock units. On February 27, 2026, 6,577 restricted stock units were exercised into 6,577 shares of common stock at $0.00 per share, reflecting a vesting event rather than an open‑market purchase. On the same date, 2,786 shares of common stock were disposed of at $21.52 per share to satisfy tax obligations through share withholding, not a market sale. Following these transactions, Foukas directly held 3,791 shares of common stock and 66,693 restricted stock units, each representing a contingent right to receive one share of USANA common stock.
USANA Health Sciences CEO and executive chairman Kevin Guest reported equity award activity involving restricted stock units and common stock. On February 27, 2026, he exercised 7,856 restricted stock units, converting them into 7,856 shares of common stock at a stated price of
USANA Health Sciences chief information officer Peter Benedict reported equity award activity involving restricted stock units and common shares. On February 27, 2026, he exercised 3,906 restricted stock units, each convertible into one share of USANA common stock, and received 3,906 common shares at a stated price of